ID   TOV-112DR
AC   CVCL_IQ56
SY   TOV112DR
DR   cancercelllines; CVCL_IQ56
DR   PRIDE; PXD003668
DR   Wikidata; Q54972796
RX   PubMed=27561551;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:31355; Carboplatin (CBP; Paraplatin).
CC   Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser37Ala (c.109T>G); ClinVar=VCV000376235; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11100; SMARCA4; Simple; p.Leu639fs (c.1915delC); Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (from parent cell line).
CC   Omics: Deep proteome analysis.
CC   Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
DI   NCIt; C7979; Ovarian endometrioid adenocarcinoma
DI   ORDO; Orphanet_454723; Endometrioid carcinoma of ovary
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_3612 ! TOV-112D
SX   Female
AG   42Y
CA   Cancer cell line
DT   Created: 03-03-17; Last updated: 05-10-23; Version: 10
//
RX   PubMed=27561551; DOI=10.1038/ncomms12645;
RA   Coscia F., Watters K.M., Curtis M., Eckert M.A., Chiang C.-Y.,
RA   Tyanova S., Montag A., Lastra R.R., Lengyel E., Mann M.;
RT   "Integrative proteomic profiling of ovarian cancer cell lines reveals
RT   precursor cell associated proteins and functional status.";
RL   Nat. Commun. 7:12645.1-12645.14(2016).
//